Should I Buy LIVN? LIVN 2026 Analysis

Should You Buy LivaNova PLC (LIVN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

66.560

1 Day change

2.35%

52 Week Range

67.920

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price ($66.8) is pressing into near-term resistance (R1 ~$67.14) with momentum (MACD histogram) still positive but contracting.
Near-term odds skew slightly negative based on the provided pattern study (next week/month expected drift lower), which reduces the edge of chasing at current levels.
Upside case exists (bullish longer-term trend + multiple bullish analysts), but with earnings on 2026-02-25 pre-market and elevated implied volatility, the risk/reward for buying immediately is not compelling.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bullish structure with moving averages aligned positively (SMA_5 > SMA_20 > SMA_200), supporting an intermediate uptrend.
Momentum: MACD histogram is positive (0.198) but contracting, suggesting upside momentum is fading near resistance.
RSI: RSI_6 = 58.16 (neutral) — not overbought, but also not a strong “oversold bounce” setup.
Key levels: Pivot ~$65.05 (first support reference). Resistance at R1 ~$67.14 and R2 ~$68.43; supports at S1 ~$62.96 and S2 ~$61.67.
Price location: At $66.8, the stock is close to R1, which often limits immediate upside unless volume/momentum expands.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call ratio of 0.56 suggests relatively more call positioning than puts (constructive sentiment).
Activity: Options volume is call-only today (15 calls vs 0 puts), but overall volume is still small, so sentiment signal is modest.
Volatility: 30D IV ~58.76 with IV percentile ~76.89 indicates options are priced rich vs their own history (market pricing in higher uncertainty/possible move, consistent with upcoming earnings).
Takeaway: Options market leans bullish in positioning, but elevated IV reduces attractiveness of initiating new long stock exposure right here (you’re effectively paying up for uncertainty).

Technical Summary

Sell

Buy

Positive Catalysts

- Bullish technical backdrop (moving-average stack is positive), indicating the longer-term trend remains constructive.
- Analyst support is improving overall: multiple Outperform/Overweight ratings with targets well above spot (notably KeyBanc $81; Baird $75; Mizuho $72).
- Upcoming earnings (QDEC 2025 on 2026-02-25 pre-market) could serve as a catalyst if results/margins re-accelerate or guidance surprises to the upside.

Neutral/Negative Catalysts

- Near-term momentum is weakening (MACD histogram contracting) while price is near resistance (~$67.14), which is a common spot for stalls/pullbacks.
- Statistical pattern outlook provided implies mild downside bias over the next week/month.
- Elevated implied volatility into earnings increases event-risk; if results/guidance disappoint, downside can be sharper.
- Latest reported quarter shows profit/margin pressure despite revenue growth (quality of growth concern).

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $357.753M, +12.46% YoY (solid top-line growth).
Profitability: Net income $26.784M, -18.72% YoY; EPS $0.49, -18.33% YoY (earnings contraction).
Margins: Gross margin 68.44%, down 3.35% YoY (margin compression is the key negative trend).
Read-through: Growth is strong, but the market likely needs evidence that margins/EPS re-accelerate for the stock to break out sustainably.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Price targets have been revised upward across multiple firms in late 2025/early 2026.
Mixed stance at the top: Barclays raised PT to $67 (Equal Weight) and Goldman raised PT to $66 (Neutral) — both roughly around the current price, implying limited near-term upside in their base cases.
Bull case: KeyBanc initiated Overweight with an $81 PT citing an underappreciated inflection and a pathway to improved margins; Baird and Mizuho maintain Outperform with ~$75 and ~$72 PTs.
Wall Street pros vs cons:
- Pros: Underappreciated growth/margin inflection narrative, multiple bullish PTs well above spot.
- Cons: Some major banks remain Neutral/Equal Weight with targets near current price, reflecting uncertainty that revenue growth converts into stronger earnings/margins.

8 Analyst Rating

Wall Street analysts forecast LIVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIVN is 72.5 USD with a low forecast of 64 USD and a high forecast of 85 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

2 Hold

0 Sell

Strong Buy

Current: 65.030

Low

Averages

72.5

High

Current: 65.030

Low

Averages

72.5

High

Barclays

Equal Weight

maintain

$58 -> $67

AI Analysis

2026-01-09

Reason

Barclays

Price Target

$58 -> $67

AI Analysis

2026-01-09

maintain

Equal Weight

Reason

Barclays raised the firm's price target on LivaNova to $67 from $58 and keeps an Equal Weight rating on the shares. The firm cites an increased target multiple, in line with the recent increase in comparable stocks, for the target boost.

Goldman Sachs

David Roman

Neutral

maintain

$56 -> $66

2026-01-09

Reason

Goldman Sachs

David Roman

Price Target

$56 -> $66

2026-01-09

maintain

Neutral

Reason

Goldman Sachs analyst David Roman raised the firm's price target on LivaNova to $66 from $56 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LIVN

Unlock Now

LIVN Should I Buy

LIVN Should I Buy

Should You Buy LivaNova PLC (LIVN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch